{"nctId":"NCT00081770","briefTitle":"Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)","startDateStruct":{"date":"2004-03"},"conditions":["Hepatitis C, Chronic"],"count":4469,"armGroups":[{"label":"PegIntron 1.5 ug/kg/wk plus REBETOL","type":"EXPERIMENTAL","interventionNames":["Biological: PegIntron (peginterferon alfa-2b; SCH 54031)","Drug: REBETOL (ribavirin; SCH 18908)"]},{"label":"PegIntron 1.0 ug/kg/wk plus REBETOL","type":"EXPERIMENTAL","interventionNames":["Biological: PegIntron (peginterferon alfa-2b; SCH 54031)","Drug: REBETOL (ribavirin; SCH 18908)"]},{"label":"PEGASYS 180 ug/wk Plus COPEGUS","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: PEGASYS (peginterferon alfa-2a)","Drug: COPEGUS (ribavirin)"]}],"interventions":[{"name":"PegIntron (peginterferon alfa-2b; SCH 54031)","otherNames":["PegIntron"]},{"name":"PegIntron (peginterferon alfa-2b; SCH 54031)","otherNames":["PegIntron"]},{"name":"REBETOL (ribavirin; SCH 18908)","otherNames":["REBETOL [the Schering-Plough brand name for ribavirin]"]},{"name":"PEGASYS (peginterferon alfa-2a)","otherNames":["PEGASYS"]},{"name":"COPEGUS (ribavirin)","otherNames":["COPEGUS [the Hoffman-La Roche brand name for ribavirin]"]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA:\n\n* Previously untreated adults with chronic hepatitis C (hepatitis C virus ribonucleic acid \\[HCV RNA\\] quantitative polymerase chain reaction \\[qPCR\\] plasma positive)\n* Individuals with HCV genotype 1 (mixed 1a/1b is acceptable)\n* Compensated liver disease\n* Pretreatment liver biopsy slides available\n* Adults aged 18-70\n* Individuals weighing 88-275 pounds (40-125 kg)\n* Free from substance abuse for past 2 years\n* Those suffering from diabetes and/or hypertension must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)\n* Patients and partners of patients willing to use adequate contraception during the course of the study\n* Hematology laboratory results of:\n\n  * Hemoglobin (HGB) ≥ 12 g/dL for females or ≥ 13g/dL for males\n  * White Blood Cell Count (WBC) ≥ 3,000/mm\\^3\n  * Neutrophils ≥ 1,500/mm\\^3\n  * Platelets ≥ 80,000/mm\\^3\n* Chemistry laboratory results of:\n\n  * Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and direct bilirubin\n  * Antinuclear antibody (ANA) ≤ 1:320\n  * Fasting Glucose 70-140 mg/dL Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, glycosylated hemoglobin \\[HbA1C\\] must be ≤ 8.5%\n\nEXCLUSION CRITERIA:\n\n* Previous hepatitis C treatment\n* Pregnant women or partners of pregnant women\n* Patients or partners of patients who intend to become pregnant any time during the 48 weeks\n* Women who are breastfeeding\n* Individuals with liver disease not caused by hepatitis C\n* Individuals infected with the hepatitis B virus and/or human immunodeficiency virus (HIV)\n* Patients with a history of liver cancer (hepatocellular carcinoma)\n* Known blood disorders such as hemoglobinopathy, coagulopathy, or glucose-6-phosphate dehydrogenase \\[G6PD\\] deficiency\n* Body organ transplant\n* Any known or suspected cancer within the past 5 years\n* Individuals who currently use epoetin \\[EPO\\], granulocyte colony stimulating factor \\[G-CSF\\] and/or granulocyte monocyte colony stimulating factor \\[GM-CSF\\]\n* Those having a history of or active clinical gout\n* Individuals who have chronic pulmonary disease\n* Individuals who have a medical condition that would likely require systemic steroids\n* Those with a history of central nervous system (CNS trauma) or seizure disorders\n* Current or previous use of lithium or antipsychotic drugs\n* Individuals who currently have or show signs of moderate to severe depression or history of significant psychiatric disorders\n* Patients with clinically significant electrocardiogram (ECG) abnormalities\n* Individuals with serious heart problems such as those who have had a heart attack, uncontrolled high blood pressure, or other heart problems\n* Patients that weigh \\> 231-275 pounds (105-125 kg) AND have a body mass index (BMI) \\> 30 AND have 3 or more of the risk factors below: (a) Strong family history of coronary heart disease (CHD) which includes 2 or more first-degree relatives with CHD or family history of early CHD at age \\< 55 for male relatives or \\< 65 for female relatives (b) Individuals with abnormal total cholesterol and/or sub fractions (uncontrolled hypercholesterolemia) (c) Diabetes (d) Hypertension (e) Smoking","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sustained Virologic Response (SVR) Rate","description":"SVR rate is the percentage of participants with undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at the end of the 24-week post-treatment follow-up.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"38.0","spread":null},{"groupId":"OG002","value":"40.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Log Viral Load at Treatment Week 4","description":"The difference between viral load levels in the blood at the start of the study and Treatment Week 4, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.32","spread":"1.50"},{"groupId":"OG001","value":"-2.02","spread":"1.42"},{"groupId":"OG002","value":"-2.45","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"Virologic Response Rate at Treatment Week 12","description":"Percentage of participants with undetectable hepatitis C RNA (HCV-RNA) at Treatment Week 12","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.9","spread":null},{"groupId":"OG001","value":"36.0","spread":null},{"groupId":"OG002","value":"45.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Log Viral Load at Treatment Week 2","description":"The difference between viral load levels in the blood at the start of the study and Treatment Week 2, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.55","spread":"1.20"},{"groupId":"OG001","value":"-1.30","spread":"1.12"},{"groupId":"OG002","value":"-1.60","spread":"1.24"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":88,"n":1019},"commonTop":["FATIGUE","HEADACHE","INSOMNIA","NAUSEA","CHILLS"]}}}